reiter outperform rate share gilead
increas price target follow better
expect oper result increas confid
trough earn year strong hiv growth outpac hcv declin
emerg data next month larg categori
cell therapi immunolog nash expect continu multipl
gilead report oper result today market close
provid updat key initi overal result better
expect non-gaap ep vs consensu
total revenu vs consensu strong revenu
growth sequenti support slower declin hcv
product sale better expect hiv product sale
particular truvada complera stribild biktarvi
follow strong result guid trough
focu key product trend assumpt hiv product sale
growth year-over-year sequenti highlight
continu shift toward taf base regimen
prescript volum vs biktarvi growth particular
highlight come mix patient switch well
new patient start expect overtak genvoya
success new hiv product launch separ declin hcv
product declin seen moder sequenti declin
yescarta cell therapi sale came slightli
consensu although highlight certif
treatment center cover elig patient
final addit focu key pipelin program upcom
event highlight upcom phase stellar data
non-alcohol steatohepat nash
precommerci activ begin recent failur selonsertib
alcohol hepat ah said read-through nash
given differ diseas biolog high rate decompens cirrhosi
high mortal rate progress inhibitor
filgotinib also note posit data psoriat arthriti
ulcer coliti uc upcom phase data
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
non-gaap ep exclud stock-bas compens reflect adjust
compani prioriti stock list
compani data secur llc estim reuter
compani report secur llc estim factset
gilead scienc report result today close compani report total revenu
billion vs billion consensu year-over-year quarter-over-quart
billion revenu compris billion product sale million royalti contract
revenu compar billion product sale million royalti
contract revenu year-ago period non-gaap ep
favor settlement tax examin vs consensu
term expens gross margin vs non-gaap expens
non-gaap sg expens
year-ago period primarili due growth cost associ recent acquisit kite pharma
compani non-gaap oper margin quarter compar
compani held cash cash equival june vs end
guidanc
updat full-year guidanc initi provid februari product sale guidanc
project rang billion non-gaap gross margin guidanc non-
 expens guidanc forecast rang billion non- sg expens
guidanc rang billion guidanc non-gaap effect tax rate
impact non-gaap adjust expect rang
hiv product global sale yoy sequenti primarili driven
higher demand taf-bas regimen global sale descovi ftc/taf -base regimen biktarvi
genvoya odefsey descovi yoy sequenti taf-
base regimen account gild prescript volum vs eu taf-
base regimen account hiv product revenu taf-bas regimen continu
prescrib hiv regimen treatment across nave switch patient across nave
patient genvoya also repres success hiv launch first hiv
product reach annual sale
us biktarvi sale million full first quarter sale sinc approv
biktarvi prescript come switch approxim switch came
gonvoya anoth quarter regimen contain dolutegravir biktarvi approv eu
june price reimburs discuss expect take place next
month anticip biktarvi overtak genvoya success hiv launch
number one regimen treatment-nav patient truvada continu growth driver
approxim peopl take truvada prep pre-exposur prophylaxi end
overal see hiv franchis growth stori
 hiv market dynam describ million patient infect
diagnos patient antiretrovir treatment includ regimen
hcv global sale yoy sequenti sequenti decreas
driven primarili stabil market dynam us hcv sale
yoy sequenti eu hcv sale yoy sequenti
intern market hcv sale yoy sequenti
number new patient start sequenti
eu sequenti japan flat sequenti
regard commerci launch newli approv adopt cellular therapi yescarta
certifi cancer center june access approxim yescarta-
elig patient note turn focu toward work center enhanc patient flow
us yescarta gener million net product revenu
continu develop strategi focus treatment prevent cure hiv
treatment novel nrti phase test nucleoside-resist
estim hiv infect individu current
receiv oral antivir therapi one reason anoth could benefit long-act
therapi pre-clin studi show therapeut level observ
day singl subcutan sc inject clinic formul evalu
healthi volunt follow singl sc inject therapeut drug level observ
day gild goal develop everi month self-inject product
hiv prevent note recent data confirm state high use
truvada prep seen decreas hiv burden contrast state low use prep
hiv burden increas use prep increas continu expect prep
data descovi
hiv cure conduct dose-rang studi agonist
broadli neutral anti-hiv envelop monoclon address innat adapt
immun respect follow complet dose-rang studi intend
evalu combin
anticip regulatori approv yescarta europ note increas invest global
product suppli specif europ leas ft facil netherland
expect becom fulli oper current suppli frozen yescarta product
europ vs fresh product local facil expect reduc product turnaround time
on-going yescarta zuma trial highlight pivot trial compar yescarta
salvag chemotherapi plu autolog stem cell transplant line therapi dlbcl expect
complet enrol trial note trial success yescarta could
allow patient avoid toxic morbid associ stem cell transplant
focu improv platform acquir kite pharma end note
month sinc acquisit complet busi develop deal includ
acquisit invest partnership recent enter collabor
gadeta privat dutch compani gadeta intend engin alpha beta cell gamma
delta tcr beyond car-t recent enter cooper research develop
agreement crada nci target patient-specif neoantigen connect
agreement leas manufactur facil close nci
selonsertib gild inhibitor late stage test non-alcohol steatohepat nash
stellar stellar trial nash patient bridg fibrosi compens cirrhosi
respect fulli enrol data expect posit regulatori file note
selonsertib could first approv drug nash begun pre-commerci preparatori
activ note trial selonsertib plu prednison versu prednison alon subject
sever alcohol hepat ah neg selonsertib develop ah
undertaken believ read ah nash comment sever ah
patient decompens liver cirrhosi high mortal
continu enthusiast inhibitor filgotinib partner glpg
announc phase data filgotinib moder sever psoriat arthriti week
score report filgotinib placebo respect separ
independ data monitor committe select phase trial filgotinib ulcer coliti
recommend studi continu phase dose filgotinib biolog nave
rheumatoid arthriti three finch phase trial complet enrol first trial read
finch compar filgotinib placebo week patient
inadequ respons biolog diseas modifi anti-arthr drug dmard
trial week durat compar filgotinib plu methotrex plu
placebo humira placebo plu plu humira placebo humira plu plu placebo
filgotinib patient inadequ respons compar filgotinib plu
placebo plu nave subject data trial expect
price target
arriv price target appli multipl ep estim risk includ
continu slow hcv patient volum emerg credibl competit threat merck
particular failur key pipelin program hbv nash failur secur meaning revenu
opportun
expect stabil hcv trend visibl trough earn offset growth hiv product
emerg pipelin focus cell therapi cancer immunolog nash support out-performance
larg cap global commercial-stag biotechnolog compani discov develop small
molecul biolog drug global leadership hiv hcv expand beyond infecti
diseas liver diseas oncolog inflammation/fibrot diseas
